FDA “Follow-On” Biologics Framework Development Will Become More Public

FDA's development of a framework for "follow-on" biologics will become a more public process after the agency resolves internal questions about scientific issues, Office of New Drugs Deputy Director Sandra Kweder, MD, said April 16

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet